1. Home
  2. All topics: A to Z
  3. Human papillomavirus

Human papillomavirus

Disease facts

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.

Read the factsheet

ECDC guidance on HPV vaccination in EU countries

This guidance partly complements and updates the 2008 and 2012 guidance documents on the introduction of HPV immunisation in EU/EEA Member States. It also covers the efficacy of the 9-valent vaccine, which was not licensed when the last guidance was published.

Read the guidance

European Immunization Week, 2020

The campaign is marked across Europe every April and aims to raise awareness of the importance of immunisation. ECDC supports the week by launching a new European Vaccination Information Portal with up to date information on human papillomavirus.

Read more

Latest outputs

News

ECDC guidance on HPV vaccination: Focus on reaching all girlsArchived

Press release -

News

Detection of human papillomavirus DNA in urine. A review of the literatureArchived

ECDC comment -

News

Introduction of human papillomavirus vaccination in Nordic countriesArchived

ECDC comment -

News

Pre-vaccination prevalence and distribution of high-risk human papillomavirus (HPV) types in Slovenian women: A cervical cancer screening based studyArchived

ECDC comment -

News

Estimated acceptance of HPV vaccination among Italian women aged 18–26 yearsArchived

ECDC comment -

News

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineArchived

ECDC comment -

News

Economic evaluation of human papilloma virus vaccination in the European Union: a critical reviewArchived

ECDC comment -

Peer-Reviewed Publication

The current state of introduction of HPV vaccination into national immunisation schedules in Europe: Results of the VENICE 2008 survey

Oct 2009

Publication

Expert opinion on the Introduction of HPV Vaccines in EU Countries

Expert opinion -

Peer-Reviewed Publication

European Centre for Disease Prevention and Control issues guidance for the introduction of human papillomavirus (HPV) vaccines in European Union countries.

Jan 2008

Facts

Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union.

Prevention and control

Two prophylactic HPV vaccines have been licensed in Europe, a bivalent and a quadrivalent vaccine: both have a good safety profile and protect against the high-risk HPV types 16 and 18.

Scientific advice

Systematic reviews, expert opinions and public health guidance on human papillomavirus.

Related topics

Disease networks

European Network for STI Surveillance

Disease groups

Vaccine-preventable diseases

Disease / public health area

Meningococcal disease

Disease / public health area

Mumps

Disease / public health area

Pertussis

Disease / public health area

Poliomyelitis

Disease / public health area

Rabies

Disease / public health area

Rotavirus infection

Disease / public health area

Rubella

Disease / public health area

Seasonal influenza

Disease / public health area

Smallpox

Disease / public health area

Tetanus

Sexually Transmitted Infections

Disease / public health area

Chlamydia infection

Disease / public health area

Congenital syphilis

Disease / public health area

Gonorrhoea

Disease / public health area

Hepatitis B

Disease / public health area

Hepatitis C

Disease / public health area

HIV infection and AIDS

Disease / public health area

Lymphogranuloma venereum

Disease / public health area

Syphilis